The effects of the nonselective benzodiazepine lorazepam and the α2/α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels

Clinical Pharmacology in Drug Development

Volumn 4, Issue 2, 2015, Pages 149-154

  te Beek, Erik T ^a   Chen, Xia ^a,b   Jacobs, Gabriël E ^a,c   Nahon, Kimberly J ^a   de Kam, Marieke L ^a   Lappalainen, Jaakko ^d   Cross, Alan J ^d   van Gerven, Joop M A ^a   Hay, Justin L ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ASTRAZENECA   (United Kingdom)

Author keywords

AZD6280; AZD7325; Healthy volunteers; Lorazepam; Prolactin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AZD 6280; AZD 7325; LORAZEPAM; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; 4-AMINO-8-(2,5-DIMETHOXYPHENYL)-N-PROPYLCINNOLINE-3-CARBOXAMIDE; 4-AMINO-8-(2-FLUORO-6-METHOXY-PHENYL)-N-PROPYLCINNOLINE-3-CARBOXAMIDE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BIOLOGICAL MARKER; FUSED HETEROCYCLIC RINGS; GABRA2 PROTEIN, HUMAN; GABRA3 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GABAERGIC SYSTEM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; GERMANY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GABA MODULATORS; GERMANY; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PROLACTIN; RECEPTORS, GABA-A; YOUNG ADULT;

EID: 85027938618     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.134     Document Type: Article

References (46)

1. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000; 3(6):587-592.
2. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999; 401(6755):796-800.
3. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000; 290(5489):131-134.
4. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci U S A. 2005; 102(3):915-920.
5. Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 2001; 22(4):188-194.
6. Dias R, Sheppard WF, Fradley RL, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci. 2005; 25(46):10682-10688.
7. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 2002; 22(13):5572-5580.
8. Crestani F, Keist R, Fritschy JM, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 2002; 99(13):8980-8985.
9. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011; 10(9):685-697.
10. Tan KR, Brown M, Labouebe G, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010; 463(7282):769-774.
11. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001; 22(6):724-763.
12. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000; 80(4):1523-1631.
13. Tappaz ML. GABA and anterior pituitary function: anatomical data. Psychoneuroendocrinology. 1984; 9(2):85-95.
14. Ondo JG, Dom R. The arcuate nucleus: a site for gamma-aminobutyric acid regulation of prolactin secretion. Brain Res. 1986; 381(1):43-48.
15. Lee TY, Pan JT. Involvement of central GABAergic neurons in basal and diurnal changes of tuberoinfundibular dopaminergic neuronal activity and prolactin secretion. Life Sci. 2001; 68(17):1965-1975.
16. Casanueva F, Apud J, Locatelli V, et al. Mechanisms subserving the stimulatory and inhibitory components of gamma-aminobutyric acid-ergic control of prolactin secretion in the rat. Endocrinology. 1981; 109(2):567-575.
17. Locatelli V, Cocchi D, Frigerio C, et al. Dual gamma-aminobutyric acid control of prolactin secretion in the rat. Endocrinology. 1979; 105(3):778-785.
18. Shin SH, Obonsawin MC, Bates L. Gamma-aminobutyric acid is not likely a physiological prolactin-inhibiting factor. Horm Res. 1984; 19(1):33-42.
19. Ajlouni K, El-Khateeb M. Effect of glucose of growth hormone, prolactin and thyroid-stimulating hormone response to diazepam in normal subjects. Horm Res. 1980; 13(3):160-164.
20. Laakmann G, Treusch J, Eichmeier A, Schmauss M, Treusch U, Wahlster U. Inhibitory effect of phentolamine on diazepam-induced growth hormone secretion and lack of effect of diazepam on prolactin secretion in man. Psychoneuroendocrinology. 1982; 7(2-3):135-139.
21. D'Armiento M, Bisignani G, Reda G. Effect of bromazepam on growth hormone and prolactin secretion in normal subjects. Horm Res. 1981; 15(4):224-227.
22. Beary MD, Lacey JH, Bhat AV. The neuro-endocrine impact of 3-hydroxy-diazepam (temazepam) in women. Psychopharmacology (Berl). 1983; 79(4):295-297.
23. Zemishlany Z, McQueeney R, Gabriel SM, Davidson M. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. Neuropsychobiology. 1990; 23(3):124-128.
24. Sevy S, Brown SL, Wetzler S, et al. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res. 1994; 53(3):219-229.
25. Guldner J, Trachsel L, Kratschmayr C, Rothe B, Holsboer F, Steiger A. Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men. Psychopharmacology (Berl). 1995; 122(2):115-121.
26. Copinschi G, Akseki E, Moreno-Reyes R, et al. Effects of bedtime administration of zolpidem on circadian and sleep-related hormonal profiles in normal women. Sleep. 1995; 18(6):417-424.
27. Melis GB, Paoletti AM, Mais V, et al. The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab. 1982; 54(3):485-489.
28. Alhambra C, Becker C, Blake T, et al. Development and SAR of functionally selective allosteric modulators of GABAA receptors. Bioorg Med Chem. 2011; 19(9):2927-2938.
29. Zhou D, Sunzel M, Ribadeneira MD, et al. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator-an in vitro and in vivo comparison. Br J Clin Pharmacol. 2012; 74(1):98-108.
30. Guo J, Davis PC, Gu C, Grimm SW. Absorption, excretion, and metabolism of a potential GABA-A alpha2/3 receptor modulator in rats. Xenobiotica. 2011; 41(5):385-399.
31. Chen X, Jacobs G, de Kam M, et al. The central nervous system effects of the partial GABA-A alpha2, 3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. Br J Clin Pharmacol. 2014; doi: 10.1111/bcp.12413
32. Chen X, Jacobs G, de Kam ML, et al. AZD6280, a novel partial GABA-A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers. 2014, Submitted.
33. Jacobs GE, Hulskotte EG, de Kam ML, et al. Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal (HPA) axis: a study in healthy volunteers. Eur Neuropsychopharmacol. 2010; 20(12):866-874.
34. Sassin JF, Frantz AG, Weitzman ED, Kapen S. Human prolactin: 24-hour pattern with increased release during sleep. Science. 1972; 177(4055):1205-1207.
35. Carlson HE, Wasser HL, Levin SR, Wilkins JN. Prolactin stimulation by meals is related to protein content. J Clin Endocrinol Metab. 1983; 57(2):334-338.
36. Quigley ME, Ropert JF, Yen SS. Acute prolactin release triggered by feeding. J Clin Endocrinol Metab. 1981; 52(5):1043-1045.
37. Liem-Moolenaar M, te Beek ET, de Kam ML, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010; 24(11):1697-1708.
38. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005; 18(3):249-255.
39. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994; 48(1):25-40.
40. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004; 65(Suppl 5):7-12.
41. Apud JA, Masotto C, Cocchi D, Locatelli V, Muller EE, Racagni G. Prolactin control by the tubero-infundibular GABAergic system: role of anterior pituitary GABA receptors. Psychoneuroendocrinology. 1984; 9(2):125-133.
42. Vilkman H, Kajander J, Aalto S, et al. The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-a double-blind randomized placebo-controlled PET study. Psychiatry Res. 2009; 174(2):130-137.
43. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem. 2002; 2(8):795-816.
44. Crestani F, Martin JR, Mohler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000; 131(7):1251-1254.
45. de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol. 2003; 55(1):39-50.
46. Chen X, de Haas S, de Kam M, van Gerven J. An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. Adv Pharmacol Sci. 2012; 2012:134523.